SLC5A2 and infection: In addition, limitations in the registry design affected our analysis, as it lacked data on the use or titration of kidney-protective therapies (e.g., sodium-glucose cotransporter 2 inhibitors and renin-angiotensin-aldosterone system blockade), nephrology-specific outcomes (e.g., access-related infection rates), and dialysis initiation methods (e.g., planned versus crash-start with temporary dialysis catheters).